source
- Apnimed upsizes IPO to $192 million to fund launch of oral sleep‑apnea drugApnimed, a Massachusetts‑based biotech, announced an upsized initial public offering that now includes 12 million shares priced at $16 each, generating $192 million in gross proceeds. This amount e…
- AbbVie shares slip 4% as Q2 immunology earnings beat falls short of lofty expectationsAbbVie’s stock fell about 4% on Friday after the company reported second‑quarter results that modestly exceeded analyst forecasts, disappointing investors who had set very high expectations. The f…